Cantor Fitzgerald Estimates RCUS FY2026 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Arcus Biosciences in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings per share of ($3.93) for the year. The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share.

Several other equities research analysts have also recently commented on the stock. Bank of America dropped their target price on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. The Goldman Sachs Group decreased their price target on shares of Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Wells Fargo & Company cut their price objective on Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Morgan Stanley decreased their target price on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. Finally, Barclays lowered their target price on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a research note on Wednesday, April 23rd. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $24.13.

Arcus Biosciences Trading Down 1.1%

RCUS stock traded down $0.10 on Tuesday, reaching $9.25. The company's stock had a trading volume of 781,402 shares, compared to its average volume of 881,231. The firm has a market cap of $979.44 million, a PE ratio of -2.94 and a beta of 0.83. The business has a fifty day simple moving average of $8.64 and a two-hundred day simple moving average of $11.26. Arcus Biosciences has a 12-month low of $6.50 and a 12-month high of $18.98. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The business had revenue of $28.00 million during the quarter, compared to the consensus estimate of $38.61 million. During the same quarter in the prior year, the business posted ($0.05) earnings per share. Arcus Biosciences's quarterly revenue was down 80.7% compared to the same quarter last year.

Institutional Investors Weigh In On Arcus Biosciences

A number of hedge funds have recently bought and sold shares of the business. Lazard Asset Management LLC boosted its stake in shares of Arcus Biosciences by 3,321.3% during the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company's stock valued at $93,000 after purchasing an additional 6,078 shares during the period. US Bancorp DE boosted its holdings in Arcus Biosciences by 2,432.0% in the fourth quarter. US Bancorp DE now owns 6,887 shares of the company's stock worth $103,000 after acquiring an additional 6,615 shares in the last quarter. Strs Ohio purchased a new stake in Arcus Biosciences during the 1st quarter worth approximately $67,000. PEAK6 LLC acquired a new position in shares of Arcus Biosciences in the 4th quarter valued at $149,000. Finally, E Fund Management Co. Ltd. acquired a new position in shares of Arcus Biosciences in the first quarter valued at about $82,000. Hedge funds and other institutional investors own 92.89% of the company's stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.